Literature DB >> 9525686

CD4-immunoglobulin G2 protects Hu-PBL-SCID mice against challenge by primary human immunodeficiency virus type 1 isolates.

M C Gauduin1, G P Allaway, W C Olson, R Weir, P J Maddon, R A Koup.   

Abstract

CD4-immunoglobulin G2 (IgG2) is a fusion protein comprising human IgG2 in which the Fv portions of both heavy and light chains have been replaced by the V1 and V2 domains of human CD4. Previous studies found that CD4-IgG2 potently neutralizes a broad range of primary human immunodeficiency virus type 1 (HIV-1) isolates in vitro and ex vivo. The current report demonstrates that CD4-IgG2 protects against infection by primary isolates of HIV-1 in vivo, using the hu-PBL-SCID mouse model. Passive administration of 10 mg of CD4-IgG2 per kg of body weight protected all animals against subsequent challenge with 10 mouse infectious doses of the laboratory-adapted T-cell-tropic isolate HIV-1(LAI), while 50 mg of CD4-IgG2 per kg protected four of five mice against the primary isolates HIV-1(JR-CSF) and HIV-1(AD6). In contrast, a polyclonal HIV-1 Ig fraction exhibited partial protection against HIV-1(LAI) at 150 mg/kg but no significant protection against the primary HIV-1 isolates. The results demonstrate that CD4-IgG2 effectively neutralizes primary HIV-1 isolates in vivo and can prevent the initiation of infection by these viruses.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9525686      PMCID: PMC109861     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  19 in total

1.  Jitters jeopardize AIDS vaccine trials.

Authors:  J Cohen
Journal:  Science       Date:  1993-11-12       Impact factor: 47.728

2.  Quantitation of human immunodeficiency virus type 1 in the blood of infected persons.

Authors:  D D Ho; T Moudgil; M Alam
Journal:  N Engl J Med       Date:  1989-12-14       Impact factor: 91.245

3.  Passive immunization with a human monoclonal antibody protects hu-PBL-SCID mice against challenge by primary isolates of HIV-1.

Authors:  M C Gauduin; P W Parren; R Weir; C F Barbas; D R Burton; R A Koup
Journal:  Nat Med       Date:  1997-12       Impact factor: 53.440

4.  hu-PBL-SCID mice can be protected from HIV-1 infection by passive transfer of monoclonal antibody to the principal neutralizing determinant of envelope gp120.

Authors:  J T Safrit; M S Fung; C A Andrews; D G Braun; W N Sun; T W Chang; R A Koup
Journal:  AIDS       Date:  1993-01       Impact factor: 4.177

5.  Two antigenically distinct subtypes of human immunodeficiency virus type 1: viral genotype predicts neutralization serotype.

Authors:  J R Mascola; J Louwagie; F E McCutchan; C L Fischer; P A Hegerich; K F Wagner; A K Fowler; J G McNeil; D S Burke
Journal:  J Infect Dis       Date:  1994-01       Impact factor: 5.226

6.  Failure of a human immunodeficiency virus (HIV) immune globulin to protect chimpanzees against experimental challenge with HIV.

Authors:  A M Prince; B Horowitz; L Baker; R W Shulman; H Ralph; J Valinsky; A Cundell; B Brotman; W Boehle; F Rey
Journal:  Proc Natl Acad Sci U S A       Date:  1988-09       Impact factor: 11.205

7.  Quantitative assessment of human immunodeficiency virus type 1 replication in human xenografts of acutely infected Hu-PBL-SCID mice.

Authors:  R A Koup; R M Hesselton; J T Safrit; M Somasundaran; J L Sullivan
Journal:  AIDS Res Hum Retroviruses       Date:  1994-03       Impact factor: 2.205

8.  Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS).

Authors:  F Barré-Sinoussi; J C Chermann; F Rey; M T Nugeyre; S Chamaret; J Gruest; C Dauguet; C Axler-Blin; F Vézinet-Brun; C Rouzioux; W Rozenbaum; L Montagnier
Journal:  Science       Date:  1983-05-20       Impact factor: 47.728

9.  Prevention of HIV-1 infection in chimpanzees by gp120 V3 domain-specific monoclonal antibody.

Authors:  E A Emini; W A Schleif; J H Nunberg; A J Conley; Y Eda; S Tokiyoshi; S D Putney; S Matsushita; K E Cobb; C M Jett
Journal:  Nature       Date:  1992-02-20       Impact factor: 49.962

10.  Human immunodeficiency virus infection of human-PBL-SCID mice.

Authors:  D E Mosier; R J Gulizia; S M Baird; D B Wilson; D H Spector; S A Spector
Journal:  Science       Date:  1991-02-15       Impact factor: 47.728

View more
  10 in total

1.  Structural flexibility and functional valence of CD4-IgG2 (PRO 542): potential for cross-linking human immunodeficiency virus type 1 envelope spikes.

Authors:  P Zhu; W C Olson; K H Roux
Journal:  J Virol       Date:  2001-07       Impact factor: 5.103

Review 2.  Inhibition of HIV-1 entry by antibodies: potential viral and cellular targets.

Authors:  S Phogat; R T Wyatt; G B Karlsson Hedestam
Journal:  J Intern Med       Date:  2007-07       Impact factor: 8.989

3.  Virus isolates during acute and chronic human immunodeficiency virus type 1 infection show distinct patterns of sensitivity to entry inhibitors.

Authors:  Peter Rusert; Herbert Kuster; Beda Joos; Benjamin Misselwitz; Cornelia Gujer; Christine Leemann; Marek Fischer; Gabriela Stiegler; Hermann Katinger; William C Olson; Rainer Weber; Leonardo Aceto; Huldrych F Günthard; Alexandra Trkola
Journal:  J Virol       Date:  2005-07       Impact factor: 5.103

4.  Interactions between natural killer cells and antibody Fc result in enhanced antibody neutralization of human immunodeficiency virus type 1.

Authors:  Donald N Forthal; Gary Landucci; Tran B Phan; Juan Becerra
Journal:  J Virol       Date:  2005-02       Impact factor: 5.103

Review 5.  Candidate antibody-based therapeutics against HIV-1.

Authors:  Rui Gong; Weizao Chen; Dimiter S Dimitrov
Journal:  BioDrugs       Date:  2012-06-01       Impact factor: 5.807

Review 6.  Closing the door to human immunodeficiency virus.

Authors:  Yuanxi Kang; Jia Guo; Zhiwei Chen
Journal:  Protein Cell       Date:  2013-03-12       Impact factor: 14.870

7.  Treatment of advanced human immunodeficiency virus type 1 disease with the viral entry inhibitor PRO 542.

Authors:  Jeffrey M Jacobson; Robert J Israel; Israel Lowy; Nancy A Ostrow; Linda S Vassilatos; Melanie Barish; Diep N H Tran; Brian M Sullivan; Thomas J Ketas; Tobias J O'Neill; Kirsten A Nagashima; Wei Huang; Christos J Petropoulos; John P Moore; Paul J Maddon; William C Olson
Journal:  Antimicrob Agents Chemother       Date:  2004-02       Impact factor: 5.191

8.  Identification and characterization of a broadly cross-reactive HIV-1 human monoclonal antibody that binds to both gp120 and gp41.

Authors:  Mei-Yun Zhang; Tingting Yuan; Jingjing Li; Andrew Rosa Borges; Jennifer D Watkins; Javier Guenaga; Zheng Yang; Yanping Wang; Richard Wilson; Yuxing Li; Victoria R Polonis; Seth H Pincus; Ruth M Ruprecht; Dimiter S Dimitrov
Journal:  PLoS One       Date:  2012-09-10       Impact factor: 3.240

Review 9.  Development of Protein- and Peptide-Based HIV Entry Inhibitors Targeting gp120 or gp41.

Authors:  Jing Pu; Qian Wang; Wei Xu; Lu Lu; Shibo Jiang
Journal:  Viruses       Date:  2019-08-01       Impact factor: 5.048

10.  Synergistic Effect by Combining a gp120-Binding Protein and a gp41-Binding Antibody to Inactivate HIV-1 Virions and Inhibit HIV-1 Infection.

Authors:  Xinling Wang; Miao Cao; Yanling Wu; Wei Xu; Qian Wang; Tianlei Ying; Lu Lu; Shibo Jiang
Journal:  Molecules       Date:  2021-03-31       Impact factor: 4.411

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.